Skip to main content

Table 4 Effect of G-hesperidin + caffeine tablets on abdominal fat area

From: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial

Parameter Group n Week-0 Week-12 Change from baseline
Total fat area (cm2) Placebo 14 301.7 ± 50.6 318.1 ± 50.4 16.3 ± 34.1
GH 15 304.3 ± 41.8 299.7 ± 44.1 −4.6 ± 20.5
GH + Caf 25 15 297.9 ± 54.8 293.7 ± 61.5 −4.2 ± 18.2
GH + Caf 50 15 295.1 ± 53.7 286.7 ± 48.9 −8.4 ± 21.9#
GH + Caf 75 15 310.8 ± 43.9 293.9 ± 45.5 −17.0 ± 31.4##
Visceral fat area (cm2) Placebo 14 97.2 ± 53.1 102.3 ± 61.9 5.1 ± 25.9
GH 15 97.6 ± 27.7 96.6 ± 27.5 −1.1 ± 15.0
GH + Caf 25 15 107.5 ± 42.3 103.6 ± 40.0 −3.8 ± 14.5
GH + Caf 50 15 108.1 ± 46.1 109.0 ± 46.6 0.9 ± 11.3
GH + Caf 75 15 101.1 ± 28.9 96.5 ± 33.7 −4.5 ± 16.1
Subcutaneous fat area (cm2) Placebo 14 204.6 ± 59.5 215.8 ± 63.5* 11.2 ± 18.3
GH 15 206.6 ± 45.4 203.1 ± 44.2 −3.5 ± 11.8
GH + Caf 25 15 190.4 ± 59.0 190.1 ± 60.1 −0.4 ± 14.3
GH + Caf 50 15 187.0 ± 48.0 177.7 ± 44.0 −9.3 ± 17.1##
GH + Caf 75 15 209.8 ± 45.4 197.3 ± 44.4* −12.4 ± 18.7##
  1. GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
  2. Mean ± SD, *p < 0.05 vs. baseline (week-0), (paired t-test), #p < 0.05, ##p < 0.01 vs. placebo